Ajanta Pharma Ltd. – Q1 Performance Briefing

$AJANTPHARM Executive Summary Ajanta Pharma reported a highly successful first quarter, driven by accelerated growth in its US generics and African institutional businesses. The robust top-line expansion and 31% profit surge underscore the company’s strong execution capabilities. In a clear signal of shareholder value creation, the board declared a substantial interim dividend of ₹32 per share. Financial & Operational Highlights The company maintained strong profitability while successfully absorbing continued investments in future growth initiatives. Financial Metric Q1 (Current) Q1 (Prior Year) YoY Change Revenue ₹1,626 crore ₹1,302.7 crore +24.8% Net Profit ₹334.2 crore ₹255.3 crore +30.9% EBITDA ₹423.6 crore ₹351.4 crore +20.6% EBITDA Margin 26.1% 27.0% -90 bps Shareholder Returns: The board declared a first interim dividend of ₹32 per equity share (face value ₹2). The total payout is approximately ₹400 crore, with a record date of August 5 and distribution on or after August 18. Segmental Breakdown The quarter showcased exceptional performance across nearly all key geographies: US Generics: The standout growth driver, with revenue surging 57% to ₹487 crore. India Branded Generics: The company's largest market delivered 24% growth, reaching ₹509 crore. This segment significantly outperformed the Indian Pharmaceutical Market (IPM) by 36%, fueled by volume expansion and strong new product launches. Africa: The Institutional business posted a remarkable 83% growth, while the Branded business expanded by 30%. Asia Branded Generics: The sole weak spot in the portfolio, experiencing a 16% revenue contraction to ₹255 crore. Following the earnings announcement, shares reacted positively, climbing to an intraday high of ₹3,531.90 on the NSE.